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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic progressive, inflammatory and destructive autoimmune
disease, characterised by synovial joint inflammation and bone erosion. To better understand the pathophysiology
and underlying immune mechanisms of RA various models of arthritis have been developed in different inbred
strains of mice. Establishment of arthritis models with components of adaptive immunity in the C57BL/6J strain of
mice has been difficult, and since most genetically modified mice are commonly bred on this background, there is
a need to explore new ways of obtaining robust models of arthritis in this strain. This study was undertaken to
establish and characterise a novel murine model of arthritis, the delayed-type hypersensitivity (DTH)-arthritis model,
and evaluate whether disease can be treated with compounds currently used in the treatment of RA.
Methods: DTH-arthritis was induced by eliciting a classical DTH reaction in one paw with methylated bovine
serum albumin (mBSA), with the modification that a cocktail of type II collagen monoclonal antibodies was
administered between the immunisation and challenge steps. Involved cell subsets and inflammatory mediators
were analysed, and tissue sections evaluated histopathologically. Disease was treated prophylactically and
therapeutically with compounds used in the treatment of RA.
Results: We demonstrate that DTH-arthritis could be induced in C57BL/6 mice with paw swelling lasting for at
least 28 days and that disease induction was dependent on CD4+ cells. We show that macrophages and
neutrophils were heavily involved in the observed pathology and that a clear profile of inflammatory mediators
associated with these cell subsets was induced locally. In addition, inflammatory markers were observed
systemically. Furthermore, we demonstrate that disease could be both prevented and treated.
Conclusions: Our findings indicate that DTH-arthritis shares features with both collagen-induced arthritis (CIA) and
human RA. DTH-arthritis is dependent on CD4+ cells for induction and can be successfully treated with TNFa-
blocking biologics and dexamethasone. On the basis of our findings we believe that the DTH-arthritis model could
hold potential in the preclinical screening of novel drugs targeting RA. The model is highly reproducible and has a
high incidence rate with synchronised onset and progression, which strengthens its potential.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease characterized by severe synovitis leading
to the destruction of articular cartilage and bone ero-
sion. This ultimately results in joint destruction and
severe disability and decreased quality of life for the
affected patients [1]. Although the precise etiology and
pathogenesis of RA remain unknown, several therapeu-
tic advances have been made in recent years, most nota-
bly through blockade of tumor necrosis factor (TNF)
[2,3].
To develop targeted therapeutic interventions, such as
the TNF-blocking biologics currently on the market,
investigators must attempt to dissect the multi-factorial
nature of RA pathogenesis through the use of animal
models mimicking different aspects of the disease. One
animal model cannot stand alone, and in the pre-clinical
screening of potential therapeutics, it is advantageous to
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use a range of different models that can supplement
each other in the final evaluation of a drug candidate.
Indeed, the predictive value of anti-rheumatic drug effi-
cacy in pre-clinical animal models of RA is greatly
enhanced if the pre-clinical efficacy testing is conducted
using several different animal models [4,5].
Several animal models of arthritis exist, but none of
them truly represents the human condition. Most
likely each model mimics certain aspects and thus can
be used as tools to increase the understanding of spe-
cific pathways of the disease. In the murine collagen-
induced arthritis (CIA) model, disease is induced by
immunization with type II collagen (CII) in an adju-
vant. This approach leads to activation of CII-specific
T cells and generation of anti-CII-specific autoantibo-
dies and results in polyarthritis characterized by severe
synovitis, cartilage destruction, and bone erosion [6,7].
Furthermore, it is possible to induce transient polyar-
thritis in mice on the basis of passive transfer of
monoclonal anti-CII antibodies - anti-type II collagen
antibody-induced arthritis (CAIA) [8,9]. The disease
pathogenesis differs in the two models. Arthritis in
CIA mice is a combination of a delayed-type hypersen-
sitivity (DTH) reaction and an immune complex dis-
ease of the joint, and the disease is dependent on T
and B cells [10-12]. The arthritis that develops in
CAIA is a combination of immune complex disease
and innate immune cell-mediated tissue destruction of
the joint, in which the administered anti-CII coats the
cartilage surface and leads to complement activation
and Fc receptor-mediated activation of cells of the
innate immune system [8,13-15]. Disease in CAIA
arises independently of T and B cells. CIA susceptibil-
ity is dependent on major histocompatibility complex
(MHC), and only strains carrying the H-2q or H-2r
haplotype are susceptible. The DBA1 strain has the H-
2q haplotype, and male mice of this strain are the most
commonly used [16]. C57BL/6 mice have the H-2b
haplotype and thus are considered refractory to CIA
under normal circumstances [17].
In 2007, Tanaka and colleagues [18], using male
BALB/c mice, described a new arthritis model - termed
DTH arthritis - in which arthritis can be induced in a
single paw by immunization with methylated bovine
serum albumin (mBSA) combined with injection of a
low dose of an anti-CII antibody cocktail (anti-CII) fol-
lowed by challenge with mBSA locally in the paw. The
disease is characterized by severe paw swelling, infiltra-
tion of inflammatory cells, hyperplasia of the synovial
membrane, cartilage destruction, and bone erosion, and
it is thought that the local T cell-mediated DTH
response to mBSA in conjunction with the presence of
antibodies against collagen II gives rise to the arthritic
phenotype.
In this study, we aim to establish the DTH arthritis
model in female C57BL/6 mice and characterize the
involved cell populations and cytokines. The motivation
for the transfer to this strain is the prospect of geneti-
cally modified mouse studies, which are most often on a
C57BL/6 background. A robust arthritis model on a
C57BL/6 background thus would be of considerable
value as a tool for understanding the disease process
and evaluating novel therapeutics. We confirm and
extend the previous publication [18] by demonstrating
that arthritic disease can be induced in C57BL/6 mice.
Disease induction is dependent on CD4+ cells, and
macrophages, neutrophils. Osteoclasts are also heavily
involved in the pathology. A clear profile of cytokines
and chemokines associated with these cell subsets is
induced locally in the diseased tissue. Furthermore, we
demonstrate that disease can be both prevented and
treated with compounds approved for the treatment of
RA in the clinic.
Materials and methods
Animals
Female C57BL/6J mice (Taconic, Bomholtvej, Denmark)
were used at 6 to 8 weeks of age. Animals were housed
in a facility with a 12-hour light/dark cycle and with
free access to water and standard rodent chow (Altro-
min®; Altromin Spezialfutter GmbH & Co. KG, Lage,
Germany). All animal experiments have been conducted
according to Danish legislation and have been approved
by the Danish Animal Inspectorate and the local ethical
review board.
Induction and assessment of DTH arthritis
On day minus 7, the mice were immunized with mBSA
(Sigma-Aldrich, St. Louis, MO, USA) emulsified in com-
plete Freund’s adjuvant (CFA) (Difco, Detroit, MI, USA)
intradermally at the base of the tail. Four days later,
they received 1,000 μg (approximately 50 mg/kg) CII
mouse antibody 5-clone cocktail (Chondrex, Redmond,
WA, USA) containing the clones A2-10 (IgG2a), F10-21
(IgG2a), D8-6 (IgG2a), D1-2G (IgG2b), and D2-112
(IgG2b) intravenously in 200 μL of phosphate-buffered
saline (PBS). On day 0, the mice were challenged with
200 μg of mBSA subcutaneously in 20 μL of PBS in the
right footpad. The left footpad was given 20 μL of PBS
only and served as a control. Paw swelling was mea-
sured by using a dial thickness gage (Mitutoyo, Kana-
gawa, Japan) and was calculated as right paw thickness
minus left paw thickness. Results are displayed as mean
± standard error of the mean (SEM). The clinical score
was based on the following scoring system: 0 = normal,
1 = slight swelling of the footpad or digits, 2 = moderate
swelling of the footpad or ankle or both, and 3 = severe
swelling of the entire paw and ankle. Clinical score
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results are displayed as the median. The results are
representative of at least five experiments.
Histopathological evaluation of DTH arthritis and
immunohistochemistry
Hind paws were sampled and processed by standard his-
topathological procedures. Briefly, paws were fixed in 4%
paraformaldehyde before decalcification for 7 days in
formic acid bone decalcifier (Immunocal; Decal Chemi-
cal Corporation, Tallman, NY, USA). The tissue samples
were dehydrated and embedded in paraffin before sec-
tions of 3 to 5 μm were prepared and deparaffinized.
For histopathological evaluation, sections were stained
by using a conventional hematoxylin and eosin (H&E)
tissue stain. For detection of osteoclasts, a histochemical
stain for the osteoclast enzyme tartrate-resistant acid
phosphatase (TRAP) was performed. Deparaffinized sec-
tions were stained in a TRAP staining solution contain-
ing 1.35 mmol naphtol AS-MX phosphate (Sigma-
Aldrich), 0.362 mmol N, N-dimethylformamide (Fluka;
Sigma-Aldrich), 3.88 mmol Fast Red TR salt (Sigma-
Aldrich), 0.5 mmol manganese chloride (Sigma-Aldrich),
and 25 mmol sodium tartrate (Sigma-Aldrich) in 0.1 M
Tris buffer and then were counterstained with hematox-
ylin. Cell nuclei appeared blue, and the osteoclast cyto-
plasm appeared red. For evaluation of cartilage
destruction, the Safranin O staining protocol, which
stains cartilage proteoglycan red, was used. Briefly, the
deparaffinized sections were first counterstained with
hematoxylin before staining in 0.1% Safranin O (BDH
Chemicals, Poole, UK) in distilled water followed by
staining in 0.1% Fast Green (Sigma-Aldrich) in distilled
water to provide the green tissue contrast. For immuno-
histochemical detection of F4/80+, monoclonal rat anti-
mouse F4/80 (Abcam, Cambridge, UK) was used, and
rat IgG2b (BD Pharmingen, San Diego, CA, USA) was
used as isotype control. These were diluted 1:250 and
incubated with the tissue sections overnight at 4°C.
Prior to incubation, antigen was retrieved by using Pro-
teinase K (Roche, Basel, Switzerland). Detection was car-
ried out with rabbit anti-rat antibodies (Dako, Glostrup,
Denmark) followed by incubation in EnVision+ System
horseradish peroxidase-labeled polymer anti-rabbit anti-
body (Dako). To visualize the target, sections were trea-
ted with 3-3’-diamino-benzidine-tetrahydrochloride
(Sigma-Aldrich) for 5 minutes. The sections were all
digitally scanned and studied by using a NanoZoomer
Digital Pathology Virtual Slide Viewer (Hamamatsu
Photonic, Shizuoka, Japan).
Histopathological scoring of DTH arthritis paws
Pathological changes in the paws were assessed on sec-
tions stained with H&E, TRAP, and Safranin O. The
extra-articular infiltration of inflammatory cells (assessed
on a scale of 0 to 3) and arthritic changes were assessed
separately. Arthritic changes were assessed on metatarsal
and tarsal joints, where synovitis, cartilage destruction,
and bone erosion were scored separately on a scale of 0
to 3. For each of the three parameters of arthritic
changes, an average between the two joint areas was cal-
culated. In addition, new bone formation overall in the
paw was scored on a scale of 0 to 3. The histology sum
score was calculated by adding the five scores (extra-
articular infiltration, synovitis, cartilage destruction,
bone erosion, and bone formation), whereas the extra-
articular infiltration score is left out in the arthritis
score.
Antigen-specific proliferation assay
Popliteal lymph nodes from the antigen- and PBS-chal-
lenged side from animals sacrificed on day 4 after DTH-
arthritis induction were isolated and passed through a
70-μm cell strainer to produce single-cell suspensions
and placed in complete medium containing RPMI 1640
(Invitrogen Corporation, Carlsbad, CA, USA) with 1.5%
C57BL/6 mouse serum (Innovative Research, Novi, MI,
USA), 1% penicillin/streptomycin (Invitrogen Corpora-
tion), and 50 μM 2-mercaptoethanol (Invitrogen Cor-
poration). Lymph nodes draining the PBS-challenged
side were pooled. Two hundred thousand cells per well
were transferred to a 96-well plate, and 0, 5, 10, or 20
μg/mL mBSA (Sigma-Aldrich) was added. The plate was
incubated at 37°C for 72 hours before the addition of
0.5 μCi/well 3H-thymidine (Amersham, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK) and
incubation overnight. Results are displayed as mean ±
SEM counts per minute with background subtracted.
The experiment was performed once.
Enzyme-linked immunosorbent assay
Levels of serum amyloid P component (SAP) were mea-
sured in serum from mice with DTH arthritis by using
sandwich enzyme-linked immunosorbent assay (ELISA)
kits (GenWay Biotech, Inc., San Diego, CA, USA) in
accordance with the instructions of the manufacturer.
Levels of interleukin 6 (IL-6) and total (activated +
proenzyme) matrix metalloproteinase 3 (MMP3) were
measured in serum from mice with DTH arthritis by
using sandwich ELISA kits (R&D Systems, Minneapolis,
MN, USA) in accordance with the instructions of the
manufacturer. Results are displayed as mean ± SEM.
Analysis of cell subsets in the inflammatory exudates
Cells were isolated from antigen-challenged hind paws
from mice sacrificed on days 2 and 7 after DTH-arthritis
induction by incubating paw tissue for 1 hour in 50 U/
mL collagenase (Sigma-Aldrich) and 50 U/mL DNAse
(Roche) followed by washing in PBS and counting. Cells
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were stained with Fixable Near IR Vital dye (Invitrogen
Corporation), CD45-E-fluor 450, clone 30.F11
(eBioscience, San Diego, CA, USA), TCRb-PerCP Cy5.5,
clone H57-597 (eBioscience), CD4-Qdot 605, clone
RM4-5 (Invitrogen Corporation), CD19-PE-Cy7, clone
1D3 (BD Biosciences, San Jose, CA, USA), CD11c-APC,
clone HL3 (BD Biosciences), CD11b-AF700, clone M1/
70 (eBioscience), F4/80-FITC, BM8 (eBioscience), and
Ly6G-PE, clone 1A8 (BD Biosciences) and analyzed by
using the LSRII flow cytometer and FACSDiva software
version 6.1.3 (BD Biosciences). Cells were gated on sing-
lets, live cells, and CD45+ cells before individual subsets
were defined. Results are displayed as mean ± SEM for
fractions and as median for absolute cell counts and are
representative of three experiments.
Depletion of CD4+ and CD8+ cells
A dose of 1,000 μg of depleting monoclonal antibody
(mAb) against CD4 (clone GK1.5; BioXcell, West Leba-
non, NH, USA) or CD8 (clone 53.6.72; BioXcell) in 200
μL of PBS or 200 μL of PBS alone was administered 24
hours prior to immunization (day minus 8) and 24
hours prior to challenge (day minus 1). Depletion was
confirmed by flow cytometry analysis of whole-blood
samples taken 24 hours after the first depletion treat-
ment (day -7) and on day 9 after DTH-arthritis induc-
tion. The blood was stained with CD8-FITC (clone 2.43;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
CD4-PE (clone RM4-4; eBioscience), CD45-eFlour450
(eBioscience), and TcRb-APC-eFluor780 (eBioscience).
Samples were analyzed as described above. Results are
displayed as mean ± SEM, and the experiment was per-
formed once.
Multiplex analysis of cytokines in paw homogenate
Hind paws from mice with DTH arthritis were sampled
at selected times after DTH-arthritis induction and each
was placed in 1.25 mL of an ice-cold homogenization
buffer containing 49.995 mL of 0.9% saline, one tablet of
complete ethylenediaminetetraacetic acid (EDTA)-free
protease inhibitor cocktail (Roche), and 5 μL of Triton
X-100 (Sigma-Aldrich). The paws were homogenized by
using a T25 Ultraturrax homogeniser (IKA, Staufen,
Germany) followed by centrifugation at 10,000g for 15
minutes. The supernatants were decanted and centri-
fuged once more at 10,000g for 15 minutes. The result-
ing supernatants were analyzed neat for levels of TNFa,
IL-1b, IL-6, IL-17, IL-12(p40), CXCL10, CXCL2, CCL2,
interferon-gamma (IFNg), and receptor activator of
nuclear factor kappa-B ligand (RANKL) by using bead-
based Luminex® xMAP® technology with Milliplex kits
from EMD Millipore Corporation (Billerica, MA, USA)
in accordance with the instructions of the manufacturer.
Results are displayed as the median, and difference from
the control value was tested. In the analysis of cytokine
production in untreated animals, left PBS-challenged
hind paws removed on day 14 after DTH-arthritis
induction were used as controls, and the results are
representative of two experiments. In the analysis of
cytokine production in anti-TNFa mAb-treated or iso-
type control antibody-treated animals, the contralateral
left PBS-challenged hind paw was used as control, and
the analysis was performed once. Any values below the
detection limit were set to the detection limit for the
analyte in question, and any values above the detection
limit were set to the upper detection limit for the ana-
lyte in question.
TNFa blockade in vivo
Mice were treated with rat anti-mouse TNFa mAbs
(clone XT3.11; BioXcell) or rat IgG1 (HRPN; BioXcell)
in doses of 250 μg per mouse (approximately 12.5 mg/
kg) in 200 μL of PBS intraperitoneally every 48 hours
beginning at the time of immunization (prophylactic
treatment) or the time of challenge (treatment at onset)
and continuing until the end of the study (day 10 after
DTH-arthritis induction). For treatment with etanercept
(Enbrel™; Pfizer, Groton, CT, USA), the mice received
doses of 500 μg per mouse (approximately 25 mg/kg) or
1,000 μg per mouse (approximately 50 mg/kg) in 200
μL of saline intraperitoneally every 48 hours from day 1
after DTH-arthritis induction until day 11 after DTH-
arthritis induction, at which time the study was termi-
nated. Control groups received humanized anti-trinitro-
phenol (TNP) IgG1 (anti-TNP hzIgG1; Novo Nordisk
A/S, Måløv, Denmark) in accordance with the same pro-
tocol. An additional vehicle-treated group was included
and received 200 μL of saline intraperitoneally every 48
hours from the time of DTH-arthritis induction. Results
are displayed as mean ± SEM. The results of TNFa
blockade are representative of several experiments,
whereas the therapeutic etanercept treatment study was
performed once.
Dexamethasone treatment
Mice were treated daily with dexamethasone (Intervet,
Milton Keynes, UK) in doses of 1 mg/kg in 200 μL of
saline beginning at the time of DTH-arthritis onset (day
0) and continuing until day 11 after DTH-arthritis
induction, at which time the study was terminated. Con-
trol groups received no treatment. Results are displayed
as mean ± SEM, and the experiment was performed
once.
Statistics
Statistical analyses were conducted by using GraphPad
Prism software version 5.01 (GraphPad Software, Inc.,
La Jolla, CA, USA). Non-parametric data or non-normal
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parametric data were analyzed by using the Mann-Whit-
ney U test, and parametric data were analyzed by using
a two-sided unpaired t test. For statistical analysis of the
histological sum scores, an unpaired Student t test with
Welch’s correction was used. Differences between
groups were considered significant when P values were
not more than 0.05, and levels of significance were
assigned as *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
Results
Establishment of DTH arthritis in C57BL/6J mice
The DTH-arthritis model was first described by Tanaka
and colleagues in male BALB/c mice in 2007 [18]. We
aimed to transfer the model to female C57BL/6J mice
by using the experimental protocol outlined in Figure
1a. Briefly, the mice were immunized on day -7 with
mBSA emulsified in CFA; on day -3, they were given a
cocktail of anti-type II collagen antibodies (anti-CII), or
an isotype control cocktail, before challenge on day 0
with mBSA in the right hind paw and vehicle (PBS) in
the left hind paw. The findings by Tanaka and collea-
gues were confirmed by us in female BALB/c mice (data
not shown), and the model was transferred with success
to female C57BL/6J mice, in which paw swelling per-
sisted for at least 28 days (Figure 1b, c). Disease onset
was simultaneous, incidence was close to 100%, and
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Figure 1 Establishment and assessment of the delayed-type hypersensitivity (DTH)-arthritis model. (a) Protocol for induction of DTH
arthritis in mice. (b) Paw swelling (calculated as Δpaw swelling = left paw swelling - right paw swelling) on days 0 to 28 after antigen (Ag)
challenge for the group that received anti-type II collagen antibody cocktail (anti-CII) + challenge. For the other two groups, paw swelling until
day 14 after arthritis induction is shown. Mean ± standard error of the mean (SEM) is displayed (n = 9 per group). (c) Clinical score of the Ag-
challenged paw on days 0 to 28 after Ag challenge for the group that received anti-CII + challenge. For the other two groups, area under the
curve (AUC) of the paw swelling until day 14 after arthritis induction is shown. The median is shown (n = 9 per group). (d) Titration of anti-CII.
AUC for days 0 to 11 after DTH-arthritis induction is shown for the groups receiving anti-CII + challenge. For the group receiving anti-CII and no
challenge and the group receiving isotype cocktail and challenge, AUC for days 0 to 9 after DTH-arthritis induction is shown. Mean ± SEM is
shown (n = 6 to 19 per group). (e) Ag-specific proliferation assay of cells isolated from the popliteal lymph node draining either the Ag-
challenged or the phosphate-buffered saline (PBS)-challenged paw from mice receiving either anti-CII or isotype cocktail. Counts per minute
(CPM) relative to the degree of 3H incorporation are shown with mean ± SEM (n = 3) in triplicate wells. (f) Serum levels of interleukin-6 (IL-6) on
selected time points after DTH-arthritis induction. Mean ± SEM is shown (n = 5 per time point). (g) Serum levels of acute-phase protein serum
amyloid P component (SAP) on selected time points after DTH-arthritis induction. Mean ± SEM is shown (n = 5 per time point). ***P ≤ 0.001.
aCII, anti-type II collagen monoclonal antibody cocktail; i.v., intravenous; mAb, monoclonal antibody; mBSA, methylated bovine serum albumin.
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inflammation was restricted to the mBSA-challenged
paw. The control group receiving isotype control mAb
cocktail developed a transient response consistent with a
DTH response, whereas the unchallenged control group
failed to develop a response. The unimmunized control
group developed a very slight response on day 1 after
the challenge because of the local irritant effect of
mBSA (data not shown). A titration study was underta-
ken to determine the optimal sub-arthritogenic dose of
anti-CII for elicitation of a robust and sustained paw
inflammation without any signs of arthritis unrelated to
challenge with mBSA, such as swelling in any paw other
than the mBSA-challenged one or any paw swelling
before the time of mBSA challenge. The doses tested
were 12.5, 25, 50, and 75 mg/kg; 75 mg/kg anti-CII was
ruled out due to the appearance of paw swelling before
the time of mBSA challenge in three out of 10 animals
(data not shown) and thus was not deemed to be a sub-
arthritogenic dose. A dose of 50 mg/kg anti-CII resulted
in the most robust paw inflammation (Figure 1d) and
no sign of swelling in the absence of mBSA challenge,
so this dose was chosen for use in all subsequent stu-
dies. To determine whether the response was truly
restricted to the mBSA-challenged side of the animal,
we performed a 3H-thymidine incorporation assay. This
allowed us to quantify cell proliferation in response to
mBSA re-stimulation on cells isolated from the popliteal
lymph nodes excised from the antigen-challenged and
PBS-challenged sides of the animals. The results (Figure
1e) clearly demonstrate that the proliferative response to
mBSA was restricted to the lymph node draining the
mBSA-challenged footpad in animals receiving either
anti-CII or isotype control antibody cocktails. To have a
secondary readout parameter and to determine whether
DTH arthritis has a systemic disease component, serum
levels of the acute-phase protein SAP and the cytokine
IL-6 were measured. SAP (Figure 1g) and IL-6 (Figure
1f) levels in serum followed a biphasic time course and
peaked twice: 48 hours after immunization and 24 hours
(IL-6) or 48 hours (SAP) hours after the challenge. After
that, the levels of SAP remained elevated above baseline
until day 9 after arthritis induction. IL-6 levels had
returned to baseline levels by day 4 after arthritis induc-
tion. The biphasic response corresponds to the two
interventions: immunization and challenge; the use of
CFA in the immunization step probably had an effect
on the first observed peak in SAP and IL-6 levels.
Histopathological analyses were performed to evaluate
the arthritic pathology in the DTH-arthritis model, and
a scoring system was applied (see Materials and meth-
ods for details). The evaluation revealed that, in the
mBSA-challenged paw, the mice developed a severe
arthritis and peri-articular inflammation characterized
by influx of inflammatory cells, hyperplasia of the
synovial membrane and pannus formation with the pre-
sence of fibroblast-like cells, increased (compared with
unchallenged control animals) osteoclast activity
(assessed by the increase in number of TRAP-positive
cells, stained red, Figure 2a) and bone erosion, and carti-
lage destruction evidenced by loss of Safranin O staining
(Figure 2b). The arthritis was localized in the ankle, tar-
sus, and metatarsophalangeal joints of the mBSA-chal-
lenged paw. Bone erosion was evident on day 4 after
DTH-arthritis induction and afterwards, and cartilage
destruction (assessed by loss of Safranin O staining of
articular cartilage) was evident on day 2 after DTH-
arthritis induction and afterwards. Osteoclast number
was reduced by day 14 after DTH-arthritis induction
compared with days 4, 7, and 9, but no repair of the
damage to bone integrity was apparent. However, new
bone formation was observed and was most prevalent as
osteophytes adjacent to the affected joints of the paw
(Figure 2c). The histology sum score reached a peak on
day 7 after arthritis induction (Figure 2d), and the extra-
articular inflammation peaked on day 4 after arthritis
induction (Figure 2e). The sum score for arthritic
changes (calculated as the total sum score minus the
score for extra-articular inflammation) reached its peak
on days 7 to 9 after arthritis induction (Figure 2f). Neu-
trophils comprised a large proportion of the infiltrating
inflammatory cells, in both the synovial tissue and intra-
articular space on days 1 and 2 after the challenge. The
infiltration persisted on day 7 but was reduced by day
14 (Figure 3a). Increase in number of macrophages (F4/
80+ cells) was observed after the increase in neutrophils
in the tissue. Macrophages were observed in great num-
ber in the soft tissue and to a lesser degree in the intra-
articular space (Figure 3a). Fibroblast-like cells were also
observable within the hyperplastic synovial lining and
pannus tissue (Figures 2a and 3a, b), where they most
likely also contribute to the inflammatory process.
These data, taken together, demonstrated that mice
with DTH arthritis developed a semi-chronic arthritic
disease limited to the mBSA-challenged paw and drain-
ing lymph node while still displaying a systemic compo-
nent. The arthritis pathology observed included
synovitis, hyperplasia of the synovial membrane and
pannus formation, increased osteoclast activity, bone
erosion and remodeling, and cartilage destruction.
Inflammatory cell subset involvement
We next wanted to characterize the cell subsets involved
in the inflammatory response. The histological findings
described in the previous section were confirmed by
flow cytometry (Figure 3b), which showed an unchanged
neutrophil fraction on day 7 compared with day 2 after
DTH-arthritis induction and a fraction of F4/80+ cells
that tended to increase from days 2 to 7 after DTH-
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Figure 2 Development of severe arthritis in mice with delayed-type hypersensitivity (DTH) arthritis. (a) Histochemical stains for the
osteoclast-specific enzyme tartrate-resistant acid phosphatase (TRAP). Osteoclasts appear red. Arrows indicate areas with increased osteoclast
numbers and bone erosion. (b) Histochemical stain using the Safranin O protocol. Cartilage proteoglycan is stained red, and the intensity of the
red color is proportional to the proteoglycan content of cartilage. Arrows indicate areas displaying cartilage loss, which is most prominent in the
uncalcified cartilage. Mice with DTH arthritis developed severe arthritis characterized by increased cartilage degradation (as assessed by loss of
Safranin O staining) and osteoclast activity (as assessed by the increase in TRAP-positive cells) and bone erosion; synovitis and pannus formation
is also observed. The sections shown in (a) and (b) are representative of mice with DTH arthritis (immunization, anti-type II collagen antibody
cocktail (anti-CII), and antigen challenge) and of mice receiving immunization, anti-CII, and no challenge (control). Samples were taken on days 2,
4, 7, 9, and 14. (c) Osteophyte shown on day 14 after DTH-arthritis induction. Hematoxylin and eosin staining was used. B, bone; BM, bone
marrow; O, osteophyte. (d) Total sum score of histopathological changes from days 2 to 14 after DTH-arthritis induction. Maximum possible
score is 15. Mean ± standard error of the mean (SEM) is shown (n = 3 to 5). (e) The score for extra-articular inflammatory infiltration from days 2
to 14 after DTH-arthritis induction. Maximum possible score is 3. Mean ± SEM is shown (n = 3 to 5). (f) Sum score of arthritic changes
(calculated as total sum score of histopathological changes from which the score for extra-articular inflammatory infiltration has been subtracted)
from days 2 to 14 after DTH-arthritis induction. Maximum possible score is 12. Mean ± SEM is shown (n = 3 to 5). Details of the
histopathological scoring system can be found in the Materials and methods section.
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arthritis induction. In addition, the fraction of CD19+
cells increased significantly from days 2 to 7 after DTH-
arthritis induction. The same picture was seen in the
absolute cell counts; however, there was no observable
increase in macrophage numbers. The involvement of
effector T-cell subsets was investigated by treating mice
with depleting mAbs against CD4 or CD8 24 hours
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Figure 3 Composition of the inflammatory infiltrate in delayed-type hypersensitivity (DTH) arthritis. (a) Representative
immunohistochemical stains for F4/80+ cells and hematoxylin and eosin (H&E) stains from mice receiving immunization, anti-type II collagen
antibody cocktail (anti-CII), and challenge. Samples were taken on days 1 (F4/80+), 2 (H&E), 7, and 14 after DTH-arthritis induction. Unchallenged
control samples are from mice receiving immunization, anti-CII, and no challenge. Mice with DTH arthritis displayed severe inflammation
characterized by an infiltration of neutrophils and F4/80+ cells into the soft tissue and intra-articular space; neutrophils dominated in the early
stages and in the intra-articular space. Severe hyperplasia of the synovial membrane and pannus formation were also observed. (b) Flow
cytometric analysis of inflammatory infiltrate isolated from inflamed paws. Cell subsets are displayed both as fraction of total live CD45+ cells and
as absolute numbers per paw. Cells were gated on singlets, live cells, and CD45+, and cell subsets were defined as follows: neutrophils: Ly6G
+CD11bintermediate-high; macrophages: F4/80+CD11b+Ly6G-; dendritic cells (DCs): CD11b+CD11c+; T cells: TcRb+; B cells: CD19+. Median ± range is
shown (n = 5). *P ≤ 0.05, **P ≤ 0.01. TcRb+, T-cell receptor-beta-positive.
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induction of arthritis. The control group received PBS
injections. Depletion of CD4+ cells resulted in an abro-
gated paw swelling response in comparison with the
PBS-treated control group, whereas there was no effect
of depleting CD8+ cells (Figure 4a, b). Depletion was
confirmed by flow cytometry (Figure 4c-e), and although
a small fraction of CD4+ T cells remained on day -7,
this was not sufficient to induce an inflammatory
response, and by day 9 after DTH-arthritis induction, all
CD4+ T cells were depleted from the system. Together,
these data demonstrated that neutrophils were involved
in the acute stage of DTH arthritis, and the major
increase in macrophage numbers occurred after a few
days. In addition, development of DTH arthritis was
dependent on CD4+ T cells.
Since the dominant effector cell subsets locally in the
inflamed paw had been identified, it was interesting to
analyze the profile of inflammatory mediators produced
locally in the arthritic paw and their temporal pattern.
The results (Figure 5) demonstrated that IL-17 was the
first cytokine to peak (at 12 hours after arthritis induc-
tion), followed by IL-6, TNFa, IL-1b, and IFNg at 24
hours after the challenge. IL-12 appeared later, peaking
on day 4, although the results were not statistically sig-
nificant. All of the analyzed chemokines (CXCL2,

































































































Anti-CD4 mAb Anti-CD8 mAb PBS
Figure 4 The delayed-type hypersensitivity (DTH)-arthritis inflammatory response is dependent on CD4+ T cells. The response is
dependent on CD4+ cells and independent of CD8+ cells, as demonstrated by the failure of mice depleted of CD4+ cells to develop a paw
swelling response and the ability of mice depleted of CD8+ cells to develop a paw swelling response no different than that of the phosphate-
buffered saline (PBS)-treated control group. (a) Paw swelling measured over days 0 to 9 after DTH-arthritis induction. Mean ± standard error of
the mean (SEM) is shown (n = 6 to 10 per group). (b) Area under the curve (AUC) of paw swelling based on paw swelling data from days 0 to
9 after arthritis induction. Mean ± SEM is shown (n = 6 to 10 per group). ***P ≤ 0.001. (c) Percentage of CD4+ cells of total T-cell receptor-beta-
positive (TCRb+) cells measured on days -7 and 9 after DTH-arthritis induction shown for mice receiving anti-CD4 monoclonal antibody (mAb) or
PBS on days -8 and -1. The data show that CD4+ cells were efficiently depleted. Cells were gated on CD45 and TCRb. Mean ± SEM is shown (n
= 6 to 10 per group). (d) Percentage of CD8+ cells of total TCRb+ cells measured on days -7 and 9 after DTH-arthritis induction shown for mice
receiving anti-CD8 mAb or PBS on days -8 and -1. The data show that CD8+ cells were efficiently depleted. Cells were gated on CD45 and TCRb.
Mean ± SEM is shown (n = 6 to 10 per group). (e) Representative flow cytometry plots from the depletion check on day -7 demonstrating the
efficiency of the depleting mAbs. Cells were gated on CD45 and TCRb. The circled populations represent the remaining percentage of either
CD4+ or CD8+ cells of total TCRb+ cells.
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Figure 5 Local profile of inflammatory mediators in the delayed-type hypersensitivity (DTH)-arthritis response. Levels were measured by
multiplex bead-based luminex analysis on homogenate supernatants from whole paws taken at 12, 24, and 48 hours and 4, 9, and 14 days after
induction of DTH arthritis (n = 5 per time point). The line represents the median. *P ≤ 0.05, **P ≤ 0.01, compared with control value. CXCL,
chemokine (C-X-C motif) ligand; IFNg, interferon-gamma; IL, interleukin; IP-10, interferon-gamma inducible protein 10; MCP-1, monocyte chemo
attractant protein 1; RANKL, receptor activator of nuclear factor kappa-B ligand; TNFa, tumor necrosis factor-alpha.
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induction. CXCL10 remained elevated throughout the
response, whereas CCL2 and CXCL2 had decreased to
control levels again by day 14 after arthritis induction.
In addition, RANKL, a marker of osteoclast differentia-
tion and activation, was elevated from 24 hours after
arthritis induction, peaked on day 4, and had fallen to
control levels again by day 14.
Effects of TNFa blockade and dexamethasone treatment
in the DTH-arthritis model
As the DTH-arthritis model was newly established, it
was desirable to investigate whether the model
responded to treatment with biologics or small-molecule
anti-inflammatory compounds used in the treatment of
RA. Two methods of blocking TNFa were tested: eta-
nercept, a soluble TNF receptor fused to the Fc part of
human IgG, and rat anti-mouse TNFa mAb (anti-
TNFa). Anti-TNFa was administered prophylactically
from the time of immunization and as treatment at
onset from the time of mBSA challenge and in both
instances was able to significantly reduce the footpad
swelling response (Figure 6a, b). Etanercept was admi-
nistered therapeutically in doses of 25 and 50 mg/kg,
one day after disease onset when severe paw swelling
was observed, and was able to significantly reduce the
footpad swelling response when 50 mg/kg was given
(Figure 6c, d). Treatment with 25 and 50 mg/kg etaner-
cept both resulted in a significant reduction in the foot-
pad swelling response in comparison with the saline
control group (Figure 6b). The glucocorticoid dexa-
methasone was administered in doses of 1 mg/kg from
the time of disease onset and was able to significantly
reduce the paw swelling response in comparison with
the untreated control group (Figure 6e, f). These data
demonstrate that DTH arthritis responds to prophylactic
and therapeutic intervention with TNF-blocking biolo-
gics and dexamethasone. To demonstrate the effect of
treatment on multiple readouts, we performed a histo-
pathological analysis on mBSA-challenged paws from
mice treated with anti-TNFa. The results showed that
treatment with anti-TNFa led to both a reduced histol-
ogy sum score (Figure 7a) and a reduction in all of the
individual parameters analyzed (Figure 7b). We also per-
formed an analysis of the production of inflammatory
mediators in the mBSA-challenged and PBS-challenged
hind paws on days 1 and 3 after DTH-arthritis induc-
tion on mice given prophylactic treatment with anti-
TNFa mAb or the corresponding isotype control anti-
body (Figure 7c). The results demonstrated that prophy-
lactic administration of anti-TNFa mAb led to a
decrease in production of a range of inflammatory med-
iators in comparison with mice receiving the corre-
sponding isotype control antibody. In addition, there
was a significant difference between the levels in the
mBSA-challenged and contralateral PBS-challenged paw
for the majority of the analyzed inflammatory mediators
(Figure 7c), demonstrating the usefulness of the contral-
ateral PBS-challenged hind paw as an intra-animal con-
trol. IL-1b was an exception, however, as the levels of
this cytokine measured in the contralateral PBS-chal-
lenged paw were no different from the levels measured
in the mBSA-challenged paw. This could be due to an
effect of the anti-CII cocktail alone on the production of
this cytokine. We also measured serum levels of SAP
(Figure 7d) and MMP3 (Figure 7e) in mice receiving
anti-TNFa mAb. We found the serum levels of these to
be significantly lower in mice given anti-TNFa than in
mice given the isotype control antibody. Taken together,
these data demonstrate that prophylactic treatment with
anti-TNFa mAb led to significant decreases in the histo-
pathological score, the production of a range of inflam-
matory mediators locally in the mBSA-challenged paw,
and serum levels of SAP and total MMP3. In addition,
the data strengthen the value of using the contralateral
PBS-challenged paw as an intra-animal control, as there
is a significantly lower production of a range of inflam-
matory cytokines and chemokines in this paw compared
with the mBSA-challenged paw.
Discussion
In this study, we have established and characterized a
novel arthritis model, the DTH-arthritis model, in
female C57BL/6J mice. The model has been described
in male BALB/c mice [18]. We found that administering
CII between the immunization and challenge steps of an
mBSA-induced DTH reaction led to a robust T cell-
dependent arthritis of the mBSA-challenged paw as
reported by Tanaka and colleagues. We demonstrated
that paw swelling persisted for at least 28 days. Pro-
nounced involvement of neutrophils and macrophages
was shown, findings supported by the observed local
profile of inflammatory mediators. The increase in local
IL-17 production suggested an involvement of T helper
17 (Th17) cells, a T-cell subset associated with strong
inflammatory responses and autoimmunity [19,20].
However, the very early peak production of this cytokine
may also point toward the involvement of mast cells (a
cell type also observed in the inflamed joint of patients
with human RA [21]), where they have been shown to
produce IL-17 [22]. Mast cells have been found to play
a role in other murine models of arthritis [21], and the
presence and role of mast cells in DTH arthritis are cur-
rently under investigation. Histological evaluation of the
inflamed paws in the present study showed synovitis,
pannus formation, synovial hyperplasia, and bone and
cartilage destruction, reminiscent of CIA [23,24] and
human RA [25,26]. An increase in osteoclast number
was also observed and this coincided with the onset of
Atkinson et al. Arthritis Research & Therapy 2012, 14:R134
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bone erosion. This finding was further supported by the
increased production of RANKL locally in the arthritic
paw, which coincided with the increase in TRAP-posi-
tive cells on day 4 after arthritis induction. RANKL is a
TNF superfamily member expressed by osteoblasts, acti-
vated T cells, and synovial fibroblast-like cells. RANKL
exists in both a soluble and a membrane-bound form
and is an essential stimulatory factor for recruitment,
differentiation, and activation of osteoclasts. RANKL
binds to its receptor RANK, which is present on the
surface of osteoclast precursors and mature osteoclasts
[27], and the absence of RANKL prevents bone erosion
in murine arthritis [28]. In addition, the cytokines
TNFa, IL-6, IL-1, and IL-17, which are elevated early
after onset of the inflammatory response in the present
study, are known to lead to an increase in RANKL
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Figure 6 Paw swelling response in delayed-type hypersensitivity (DTH) arthritis following treatment with tumor necrosis factor alpha
(TNFa)-blocking biologics or dexamethasone. (a, b) Rat anti-mouse TNFa mAb (anti-TNFa) was administered from the time of immunization
(prophylactic), and control groups received rat IgG1 (rIgG1). Mean ± standard error of the mean (SEM) is shown (n = 9 to 10 per group). Area
under the curve (AUC) was calculated from days 0 to 10 after arthritis induction. Both prophylactic treatment and treatment at onset with anti-
TNFa resulted in a significant reduction in the footpad swelling response. (c, d) Etanercept, a soluble TNF receptor fused to the Fc part of
human IgG, was administered therapeutically (from day 1), and control groups received humanized anti-trinitrophenol (anti-TNP hzIgG1). A
vehicle (saline) control group was also included. Mean ± SEM is shown (n = 9 to 10 per group). AUC was calculated from days 0 to 10 after
arthritis induction. Therapeutic treatment with etanercept resulted in a significant reduction in footpad swelling when administered at 50 mg/kg.
Treatment with 25 and 50 mg/kg both resulted in a significant reduction in the footpad swelling response when compared with the saline
control group (indicated by ##). (e, f) Dexamethasone, a glucocorticoid, was administered daily from time of disease onset, and control groups
received no treatment. Mean ± SEM is shown (n = 9 to 10 per group). AUC was calculated from days 0 to 10 after arthritis induction. Daily
treatment with dexamethasone from time of disease onset significantly reduced the paw swelling response when compared with the untreated
control group. The levels of significance are defined as follows: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ##P ≤ 0.01.
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Figure 7 Effect of treatment with TNFa blocking biologics on histology, systemic and local inflammatory parameters. (a, b) Rat anti-
mouse tumor necrosis factor-alpha monoclonal antibody (anti-TNFa) treatment led to a significant reduction in both the histology sum score
and the individual parameters of the sum score in comparison with the control group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (c) Local profile of
inflammatory mediators following administration of anti-TNFa (n = 5 per time point). Median and range are shown. Dotted line represents levels
measured in naïve mice (n = 5). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, compared with value obtained from the mBSA-challenged paws taken from
the isotype control group. #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001, compared with the value obtained from the contralateral phosphate-buffered saline
(PBS)-challenged paws taken from animals receiving identical treatments. (d) Serum levels of serum amyloid P component (SAP) in mice given
prophylactic treatment with either anti-TNFa or isotype control antibody. Mean ± standard error of the mean (SEM) is shown (n = 5). **P ≤ 0.01,
compared with the control group. Dotted line represents levels measured in naïve mice (n = 5). (e) Serum levels the enzyme MMP3 in mice
given prophylactic treatment with either anti-TNFa mAb or isotype control antibody (rIgG1). Mean ± SEM is shown (n = 5). Dotted line
represents levels measured in naïve mice (n = 5). **P ≤ 0.01, ***P ≤ 0.001, compared with the control group. CXCL, chemokine (C-X-C motif)
ligand; IFNg, interferon-gamma; IL, interleukin; MCP-1, monocyte chemo attractant protein 1; MMP3, matrix metalloproteinase 3; RANKL, receptor
activator of nuclear factor kappa-B ligand; SAP, serum amyloid P component.
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expression [27], and these findings provide evidence that
the increased osteoclast activation observed is a result of
the inflammatory response in the affected joint. New
bone formation was also observed, albeit in an aberrant
pattern in the form of osteophytes adjacent to the
affected joints. This finding suggests that there is a dis-
turbance in the overall process of bone turnover in
DTH arthritis; this disturbance may give an opportunity
to study processes of new bone formation in inflamma-
tory arthritis.
Onset and disease course of DTH arthritis were syn-
chronized, incidence was 100% or close to it, and varia-
tion was low. These are very desirable features in an
animal model, as all animals are exposed to disease and
any treatment applied for an equal period of time. The
fact that the arthritis affects only one paw allows the
study of a more severe paw inflammation without
severely compromising animal welfare; in other estab-
lished models of arthritis, the humane endpoints set in
place to limit animal suffering are more frequently
reached, as the animals display severe inflammation in
multiple paws. In addition, the phenotype of DTH
arthritis makes the model very suitable for the applica-
tion of in vivo imaging techniques to study inflamma-
tion and bone destruction because of the presence of an
intra-animal contralateral control paw and the low
intra-group variability. Although the arthritic phenotype
is isolated to one paw, the model also displays a sys-
temic component, illustrated by the increase in serum
levels of SAP, IL-6, and total MMP3. MMP3 is notable
in this situation, as studies have shown the serum levels
of this enzyme to be a biomarker of disease severity in
RA [29]. The fact that the arthritic phenotype is induced
in only one paw, however, also represents a limitation of
the DTH-arthritis model by phenotypically removing
the animal model from the human condition that it
seeks to mimic: RA, which usually affects the joints of
multiple extremities in a symmetrical pattern. Whether
self-tolerance is broken in DTH arthritis was not inves-
tigated in the current study but remains an intriguing
possibility. Breach of self-tolerance to joint antigens has
been observed in a model of mono-arthritis, a model
also induced by an inflammatory response to an antigen
unrelated to the joint [30], the hypothesis being that
joint auto-antigens are exposed to or released from the
inflamed joint during the inflammatory response follow-
ing antigen challenge. Thus, it remains a possibility that
self-tolerance to joint-derived auto-antigens is broken in
DTH arthritis.
The role played by anti-CII antibodies in disease
induction is still not fully clear, but we hypothesize, on
the basis of our results and available literature, that
anti-CII antibodies play a role similar to what is
observed in CAIA [13-15], namely that they activate
complement and cells of the innate immune system
through Fc receptors and that these events drive the
joint pathology once the challenge with mBSA has
initiated the T cell-dependent inflammatory response.
The extent to which the anti-CII mAbs localize to the
joint space and coat the cartilage surface immediately
after administration remains unclear. It is clear, how-
ever, that there is no immediate effect of the systemic
administration of anti-CII and that the inflammatory
milieu of the DTH reaction is necessary to initiate the
events leading to joint pathology in DTH arthritis. Anti-
CII antibodies have been shown not to localize to the
joints without the presence of an exogenous trigger [31].
However, a different study demonstrated that anti-CII
antibodies coated the cartilage surface of joints without
any previous stimuli to increase vasopermeability [32].
Thus, it is still unclear whether the anti-CII localizes to
the joint space only after antigen challenge, due to the
local increase in vasopermeability caused by inflamma-
tory mediators and the effects of anti-antigen-antigen
immune complexes on complement and FcR activation
as some findings indicate [31], or whether it localizes
there immediately following administration, at which
time it is not pathogenic without further inflammatory
stimuli. These questions are currently being addressed
by means of in vivo imaging techniques. We did, how-
ever, measure equal levels of IL-1b in the mBSA-chal-
lenged and the PBS-challenged paws on days 1 and 3
after DTH-arthritis induction, and these measurements
could point toward a direct effect of the anti-CII antibo-
dies on the production of this cytokine.
We chose to qualify the model with rat anti-mouse
TNFa and etanercept (TNFRIg), which is approved for
use in the clinic to treat patients with RA. Both agents
are efficacious in several other experimental arthritis
models [33-35]. Taken together, the results from the
two treatment studies demonstrated that DTH arthritis
can be suppressed by systemic administration of TNFa-
blocking biologics whether administration was prophy-
lactic, at the time of DTH-arthritis induction, or thera-
peutic from day 1 after DTH-arthritis induction, when
paw swelling had reached peak level. In addition, block-
ing TNFa leads to effects on multiple readouts, both
systemic and local, including serum biomarkers also
useful as biomarkers in RA: MMP3 and acute-phase
proteins. Also, most of the arthritic changes observed
histopathologically were prevented when TNFa was
blocked in a prophylactic manner. Together, these
results suggest that the DTH-arthritis model of experi-
mental arthritis could have some degree of predictive
validity with regard to the therapeutic efficacy of biolo-
gics for the treatment of RA. In addition, the efficacy of
blocking TNFa suggests that DTH arthritis indeed
shares immunological pathways with human RA.
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Conclusions
In this study, we have shown that it is possible to elicit
a robust arthritis in C57BL/6 mice with synchronized
onset and progression and high incidence displaying
severe bone and cartilage destruction, something that
presents difficulties in the CAIA [15] and CIA [36,37]
models when using the C57BL/6 strain. In these mod-
els, the disease responses and incidence frequencies
observable in C57BL/6 mice are much lower and more
variable. We have verified that DTH-arthritis induction
is dependent on CD4+ T cells and anti-CII antibody-
mediated tissue damage of the joint. Moreover, we
have shown the arthritic pathology by histology and
found that it is characterized by synovitis, hyperplasia
of the synovial membrane, pannus formation,
enhanced osteoclast activity, bone erosion and remo-
deling, and cartilage destruction, features also observed
in human RA [25,26]. In addition, inflammation of the
affected joints is governed by a massive neutrophil and
macrophage infiltration, verified by flow cytometry,
histopathology, and analysis of the involved cytokines
and chemokines, which also demonstrates the involve-
ment of T cells. We have shown that disease can be
reduced by both preventive and therapeutic treatment
with TNFa-blocking biologics. Importantly, therapeutic
intervention was effective when initiated at peak of dis-
ease (day 1 after the challenge). The possibility of
robust arthritis induction in C57BL/6 mice allows stu-
dies that use genetically modified mice on a C57BL/6
background, permitting accurate comparison of disease
in wild-type and genetically modified mice, and this
represents a major advantage. Importantly, because
disease onset is pre-defined and simultaneous, the start
of a treatment plan can be standardized both within
and across treatment groups. In addition, all animals
are exposed to disease and treatment for exactly the
same amounts of time. When seen from a pharmacolo-
gical perspective, this represents an improvement com-
pared with the CIA model, the current gold-standard
arthritis model in the mouse, which has a lower and
more variable frequency of disease incidence and a
non-synchronized onset [38]. In addition, the DTH-
arthritis model is run in female mice, which are much
less prone to grouping stress than male mice and thus
are easier to house. In summary, we believe that the
DTH-arthritis model may be highly useful in the pre-
clinical screening of potential protein-based drugs tar-
geting RA, since our data demonstrate that drugs
approved for RA treatment have an effect in the
model. In addition, the model is highly suited for the
application of in vivo imaging techniques for studying
inflammation and bone remodeling and yields reliable
and reproducible data, and this strengthens its
potential. Still, additional work is needed to further
characterize the immunological mechanisms underlying
DTH arthritis and the degree to which they can be
aligned to RA pathogenesis.
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